Top Global Healthcare Growth Stocks

Top Global Healthcare Growth Stocks

UPDATED Jul 03, 2022

What are the best Global Healthcare Growth Stocks?

According to our Simply Wall St analysis these are the best Global Healthcare growth companies. We look for companies with high forecasted growth and healthy balance sheets that can deliver sustained growth over the long term.

Our criteria to find Top Growth Companies

Growth

  • Companies with sustained revenue growth that outperforms the market are attractive to investors. These companies are most likely to appreciate in share price over time.

What do we look for?

  • Is the company forecast to have high earnings growth.

Healthy Balance Sheet

  • A healthy balance sheet is essential to drive growth opportunities and sustain the business.
  • Repayments on debt take precedence over other initiatives to improve shareholder returns, so investors want to make sure the company is comfortably positioned to cover its debts.

What do we look for?

  • Does the company have a manageable level of debt.
  • Is the company able to cover its interest repayments.

50 companies meet this criteria in the Global market

Polynovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: PNV's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 48.5% below our estimate of its fair value

  • Earnings are forecast to grow 72.19% per year

  • Became profitable this year

Risks

  • Large one-off items impacting financial results

View all Risks and Rewards

Mentice AB (publ) provides endovascular simulation solutions to teaching entities, healthcare systems, and medical device manufacturers.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: MNTC is expected to become profitable in the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 44.2% below our estimate of its fair value

  • Earnings are forecast to grow 96.96% per year

Risks

  • Shareholders have been diluted in the past year

View all Risks and Rewards

Kangji Medical Holdings Limited, through its subsidiaries, designs, develops, manufactures, and sale of minimally invasive surgical instruments and accessories in China.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: 9997's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 75.9% below our estimate of its fair value

  • Earnings are forecast to grow 20.39% per year

  • Earnings grew by 82.5% over the past year

Risks

  • High level of non-cash earnings

View all Risks and Rewards

Jeisys Medical Inc. designs, develops, and manufactures medical device for plastic surgeons, dermatologist, physicians, and healthcare professionals.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: A287410's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 68.3% below our estimate of its fair value

  • Earnings are forecast to grow 21.03% per year

  • Became profitable this year

Risks

  • High level of non-cash earnings

View all Risks and Rewards

Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: CGS's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 75.4% below our estimate of its fair value

  • Earnings are forecast to grow 26.96% per year

  • Earnings grew by 2812.4% over the past year

Risks

  • Large one-off items impacting financial results

View all Risks and Rewards

Shenzhen New Industries Biomedical Engineering Co., Ltd., a bio-medical company, engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals and laboratories in China and internationally.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: 300832's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Price-To-Earnings ratio (32x) is below the CN market (34.2x)

  • Earnings are forecast to grow 26.53% per year

  • Earnings grew by 11.8% over the past year

Risks

  • High level of non-cash earnings

View all Risks and Rewards

MedApp S.A. develops mobile solutions for medicine in Poland.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: MDA's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 76.1% below our estimate of its fair value

  • Earnings are forecast to grow 43.64% per year

  • Earnings grew by 57.3% over the past year

Risks

  • High level of non-cash earnings

  • Does not have a meaningful market cap (PLN142M)

  • Does not have meaningful revenue (PLN14M)

  • Volatile share price over the past 3 months

View all Risks and Rewards

Double Medical Technology Inc. provides services, technologies, and devices in the areas of orthopedics, wound management, neurosurgery, and general surgery in China.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: 002901's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Price-To-Earnings ratio (24.5x) is below the CN market (34.2x)

  • Earnings are forecast to grow 31.49% per year

  • Earnings have grown 20.4% per year over the past 5 years

Risks

  • High level of non-cash earnings

  • Shareholders have been diluted in the past year

View all Risks and Rewards
Page 1 of 7